NCT06647550 To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
| NCT ID | NCT06647550 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Hyundai Pharm |
| Condition | Type 2 Diabetes Mellitus (T2DM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-12-12 |
| Primary Completion | 2025-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 160 participants in total. It began in 2024-12-12 with a primary completion date of 2025-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Dose-finding, Phase 2 Study to Assess the Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Eligibility Criteria
Inclusion Criteria: * Diagnosis of T2DM with HbA1c between 7.0% and 10.0% (inclusive) while on diet and exercise alone for at least 8 weeks prior to screening. Exclusion Criteria: * Type 1 diabetes or another immune-mediated diabetes syndrome * BMI: \> 40 kg/m2 * C-peptide: \< 0.5ng/mL
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06647550 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 75 Years, studying Type 2 Diabetes Mellitus (T2DM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06647550 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06647550 currently recruiting?
Yes, NCT06647550 is actively recruiting participants. Contact the research team at k50367@korea.ac.kr for enrollment information.
Where is the NCT06647550 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06647550 clinical trial?
NCT06647550 is sponsored by Hyundai Pharm. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.